ALC ALCON INC
Company Analysis
Latest News
Alcon's third quarter 2026 core EPS beat estimates despite a decline in premium lens sales
Alcon reported third quarter 2026 revenue of $2.72 billion, slightly missing analyst estimates of $2.73 billion, while core diluted EPS of $0.91 exceeded the...
Alcon AG Q3 2026 Earnings Preview: What Analysts Expect on November 10, 2026
Alcon AG is projected to report Q3 2026 revenue of $2.73 billion and core EPS of $0.89, with its current $74.94 share price sitting below the average analyst...
🟢 Alcon is trading 5% up today amid a broad-market rally
Alcon is trading 5.29% higher at $76.20 on November 4, alongside a broad-market rally; available coverage identified no fresh company-specific catalyst. - The...
🟢 Alcon is trading 4.03% up in pre-market with no company-specific catalyst identified
Alcon is trading 4.03% higher at $75.29 in pre-market on November 4; no fresh company-specific announcement explaining the move surfaced. - The provided...
🔴 Alcon is trading 8.1% down in after-hours trading with no verified company-specific catalyst identified
Alcon is trading at $65.40, down 8.12%, amid broad market weakness, though available evidence does not establish the precise cause. - No verified...
🟢 Alcon is trading 4.01% up with no confirmed company-specific catalyst
Alcon is trading 4.01% up at $70.14 on October 22, 2026; no reliable report directly links the intraday gain to a new company announcement. - The healthcare...
Alcon Secures FDA Approval for BRYTLY, Outlasting Leading Competitor by 50%
Alcon received U.S. Food and Drug Administration approval for BRYTLY, an over-the-counter (OTC) redness reliever eye drop. The product provides relief in as...
🟢 Alcon is trading 4.06% up today as investors favored defensive healthcare stocks
Alcon is trading up 4.06% at $66.46 on October 15; available market coverage points to investors favoring defensive healthcare stocks as technology shares sold...
Alcon joins White House pricing pact, part of $19.6 billion manufacturing push
Alcon and several pharmaceutical companies have entered a drug pricing agreement with the White House. The participating drug makers committed to investing...
Alcon's second quarter revenue of $2.8B and core EPS beat as company raises outlook
Alcon reported strong second quarter results driven by new product launches and robust performance in both Surgical and Vision Care segments. Net sales grew 8%...
Alcon AG Q2 2026 Earnings Preview: What Analysts Expect on August 10, 2026
Alcon AG is projected to report Q2 2026 revenue of $2.72 billion and earnings per share of $0.77, with shares currently trading at $71.81 relative to a median...
Alcon AG Q1 2026 Earnings Preview: What Analysts Expect on May 19, 2026
Alcon AG is expected to report Q1 2026 revenue of $2.70 billion and consensus earnings per share of $0.83, with the stock currently trading at $63.50 relative...
Alcon AG Q1 2026 Earnings Preview: What Analysts Expect on May 05, 2026
Alcon AG is projected to report Q1 2026 revenue of $2.71 billion and consensus EPS of $0.81, while the stock currently trades at $74.18 against a median...